

**Saskatchewan Health Authority - Saskatoon Area - ANTIBIOGRAM 2019**  
**Critical Care (ICU/CCU) PATIENTS - Non Urinary Isolates**  
**January 1, 2019 - December 31, 2019**

**ICU / CCU – % Susceptible**

	# Isolates tested	Penicillin PO/IV	Penicillin IV - meningitis	Ampicillin/Amoxicillin	Cloxacillin	Amoxicillin-Clavulanic acid	Piperacillin-Tazobactam	Cephalexin	Cefazolin	Cefoxitin	Cefuroxime	Ceftriaxone	Ceftriaxone - meningitis	Ceftazidime	Meropenem	Ertapenem	Clindamycin	Azithromycin	Erythromycin	Tetracycline/Doxycycline	Ciprofloxacin	Moxifloxacin	Trimethoprim-Sulfamethoxazole	Gentamicin	Tobramycin	Vancomycin
<b>GRAM-NEGATIVE BACTERIA</b>																										
<i>Escherichia coli</i> <sup>1</sup>	37			52		65	94		50	93		90		89	100	100					86	74		84	94	88
<i>Enterobacter cloacae</i> <sup>2 †</sup>	13			R		R	R		R	R		R		R	100	60					100	100		90	100	100
<i>Haemophilus influenzae</i>	35			57							86	100						100				100	71			
<i>Klebsiella pneumoniae</i> <sup>1 †</sup>	26			R		95	95			100		100		100	100	100					80	86		86	95	100
<i>Pseudomonas aeruginosa</i>	35						97							94	100						80			94	100	

	# Isolates tested	Penicillin PO/IV	Penicillin IV - meningitis	Ampicillin/Amoxicillin	Cloxacillin	Amoxicillin-Clavulanic acid	Piperacillin-Tazobactam	Cephalexin	Cefazolin	Cefoxitin	Cefuroxime	Ceftriaxone	Ceftriaxone - meningitis	Ceftazidime	Meropenem	Ertapenem	Clindamycin	Azithromycin	Erythromycin	Tetracycline/Doxycycline	Ciprofloxacin	Moxifloxacin	Trimethoprim-Sulfamethoxazole	Gentamicin	Tobramycin	Vancomycin	
<b>GRAM-POSITIVE BACTERIA</b>																											
<i>Staphylococcus aureus</i> , all																											
- methicillin-susceptible (MSSA)	74				100												84		84	100	96	96	96			100	
- methicillin-resistant (MRSA)	36	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	72		42	100	61	61	97			100	
<i>Staphylococcus epidermidis</i> † -	14																58		50	73	82	75	83			100	
<i>Streptococcus pneumoniae</i>	41	98	85							95	100	98		100			93		76			100				100	
Group A Streptococcus †	15	100										100					70		80							100	
<i>Enterococcus faecalis</i> †	10			100				R	R	R	R	R	R						R	50	75					100	
<i>Enterococcus faecium</i> † <sup>3</sup>	16			R				R	R	R	R	R	R						R	77	R					75	

R - intrinsically resistant

† Isolates containing less than 30 reported specimens should be interpreted using presented data ALONG WITH clinical judgement and/or input from infectious diseases service

<sup>1</sup> Overall extended spectrum beta-lactamase (ESBL) activity was seen in a weighted average of 4.8% of samples of *E.coli* and *K.pneumoniae*

<sup>2</sup> These organisms may produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility

<sup>3</sup>VRE (vancomycin-resistant Enterococci) isolated from clinical specimens: *E.faecium* 25% (N = 4)